MPLT MapLight Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1770069 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-145.1%
TTM EPS YoY162.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-293.7%
ROA-68.6%
ROIC (approx.)-812.4%
Asset turnover—
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio9.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-20.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $44.21M | $53.44M | $53.68M | $64.62M | $27.09M | $26.85M | $19.79M | $20.71M |
| SG&A expense | $11.13M | $10.11M | $10.82M | $18.75M | $4.40M | $3.82M | $3.76M | $2.06M |
| Operating income | -$55.34M | -$63.55M | -$64.50M | -$83.38M | -$31.50M | -$30.66M | -$23.54M | -$22.78M |
| Net income | -$51.62M | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | -$22.34M | -$21.23M |
| EBITDA | -$55.21M | -$63.40M | -$64.34M | -$83.24M | -$31.40M | -$30.53M | -$23.38M | -$22.58M |
| EPS (basic) | -0.97 | -1.32 | -1.34 | — | -37.18 | -39.11 | -29.33 | — |
| EPS (diluted) | -0.97 | -1.32 | -1.34 | — | -37.18 | -39.11 | -29.33 | — |
| Weighted avg. shares (diluted) | 53.10M | 45.43M | 45.28M | — | 791,127 | 763,044 | 761,598 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.57M | $71.63M | $55.71M | $46.73M | $64.15M | — | — | $38.25M |
| Short-term investments | $228.51M | $233.09M | $254.41M | $258.37M | $163.02M | — | — | $70.54M |
| Current assets | $294.60M | $318.79M | $327.23M | $324.67M | $245.31M | — | — | $114.60M |
| PP&E, net | $722,000 | $828,000 | $968,000 | $1.09M | $859,000 | — | — | $1.21M |
| Total assets | $477.18M | $368.35M | $418.79M | $479.51M | $257.22M | — | — | $136.92M |
| Current liabilities | $30.90M | $19.29M | $14.28M | $16.23M | $18.56M | — | — | $15.92M |
| Total liabilities | $31.41M | $20.05M | $18.95M | $21.14M | $23.71M | — | — | $21.72M |
| Shareholders' equity | $445.77M | $348.30M | $399.83M | $458.37M | -$274.18M | -$245.06M | -$215.83M | -$193.63M |
| Shares outstanding | 55.67M | 45.44M | 45.21M | 44.02M | 808,015 | — | — | 761,276 |
| Cash flow statement | ||||||||
| Operating cash flow | -$35.68M | -$44.87M | -$51.18M | -$46.83M | -$31.79M | -$33.97M | -$25.55M | -$21.49M |
| Capital expenditure | $12,000 | $22,000 | $24,000 | $376,000 | $31,000 | — | — | $106,000 |
| Free cash flow | -$35.69M | -$44.89M | -$51.20M | -$47.20M | -$31.82M | — | — | -$21.59M |
| Investing cash flow | -$130.07M | $60.70M | $67.01M | -$242.55M | -$135.59M | $17.43M | $37.50M | $32.39M |
| Financing cash flow | $150.55M | $92,000 | -$6.85M | $271.96M | $198.06M | -$156,000 | -$47,000 | $5,000 |
| Depreciation & amortization | $135,000 | $147,000 | $162,000 | $140,000 | $100,000 | $136,000 | $166,000 | $194,000 |
| Stock-based compensation | $10.26M | $8.63M | $9.64M | $35.52M | $125,000 | $148,000 | $212,000 | $214,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.